Cepheid Receives Emergency Use Authorization from FDA for Rapid SARS-CoV-2 Test

Cepheid today announced it has received Emergency Use Authorization (EUA) from the U.S. Food & Drug Administration (FDA) for Xpert® Xpress SARS-CoV-2 , a rapid molecular diagnostic test for qualitative detection of SARS-CoV-2 , the virus causing COVID-19. The test has been designed to operate on any of Cepheid’s more than 23,000 automated GeneXpert® Systems worldwide, with a detection time of approximately 45 minutes.


1 Like

See article in STAT about the Cepheid test for COVID-19:

New coronavirus test returns results in 45 minutes, but it may be limited to hospitals

This will be very benefecial, and in shorter TAT we cn get results. When can we expect kits in market.

Do you know the cost For each cartridge?